<DOC>
	<DOCNO>NCT01811667</DOCNO>
	<brief_summary>The phosphatidylinositol 3-kinase ( PI3Kinase ) /Protein Kinase B ( AKT ) /mammalian target rapamycin ( mTor ) pathway play role development lymphatic-vascular organisation . The investigator want study efficacy safety Rapamycin , mTor inhibitor .</brief_summary>
	<brief_title>Efficacy Safety Mammalian Target Rapamycin ( mTor Rapamycin ) Inhibitor Vascular Malformations</brief_title>
	<detailed_description>The complex vascular malformation induce chronical pain organic dysfunction cause significant morbidity mortality . Therefore , investigator need establish guideline order treat pathology . Standard treatments surgery interventional radiology limit efficacy related high level recurrence well complication . Recent preclinical study show important role PI3Kinase/AKT/mTor pathway development lymphatic-vascular organisation suggest appeal therapeutic target treat patient complex vascular malformation . The aim clinical study prospectively evaluate efficacy safety Rapamycin , mTOR inhibitor , treat child adult microcystic lymphatic malformation , general lymphatics abnormality ( GLA ) complex vascular malformation conventional therapy surgery sclerotherapy ineffective associate high risk important complication .</detailed_description>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Vascular Malformations</mesh_term>
	<mesh_term>Cardiovascular Abnormalities</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients complex vascular abnormality threat systemic therapy Patients must adequate liver function ( LDLcholesterol , triglyceride , … ) Patients must adequate organ function : neutrophil &gt; 1500/mm³ , Hb &gt; 8,0 g et platelet &gt; 50.000/mm³ ( platelet limit Kasabach Merritt syndrome ) Patients must adequate renal function ( normal creatinin depend age ) , clearance &gt; 70 ml/min/1.73m² Urin Protein Creatinine ratio &lt; 0.3 g. Karnofsky Landry &gt; 50 Dental equipment prosthesis interfere onto radiological examen Other uncontrolled medical condition ( uncontrolled diabetes , hypertension… ) Concomitant drug inhibitors/inducers cytochrome P450 3A4 ( CYP3A4 ) Immunocompromised patient , include know seropositivity HIV Digestive problem modify absorption Rapamycin ( gastric tube feed accept ) Pregnant nursing ( lactate ) woman Prior treatment phosphatidylinositol 3kinase ( PI3K ) and/or mTOR inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Vascular Abnormalities</keyword>
</DOC>